Principia Biopharma reveals data from Phase 1/2 trial targeting ITP
Category: #health  By Paroma Bhattacharya  Date: 2019-10-17
  • share
  • Twitter
  • Facebook
  • LinkedIn

Principia Biopharma reveals data from Phase 1/2 trial targeting ITP

Immune thrombocytopenia (ITP) is a type of blood abnormality that creates a shortage of blood cell fragments known as platelets required for normal blood clotting. While children with ITP get cured without treatment, adults on the other hand are required to take medication for bleeding. However, various pharmaceutical companies are still focusing on developing an effective treatment that can eliminate ITP in a short span of time.

Principia Biopharma Inc. is one such firm that has made some significant contribution in this field. The company has recently revealed preliminary data from its ongoing Phase 1/2 study of PRN1008, in a highly refractory and treatment-resistant patient population that are suffering from immune thrombocytopenia (ITP). 

Speaking on the development, Dolca Thomas, MD, Chief Medical Officer, Principia, said that the company is thrilled by the data presented and is delighted to see the scientific community recognizing this as a significant new clinical data from its oral BTK inhibitor. 

Thomas added that the company is looking forward towards sharing its findings at the oral presentation in ASH to the global hematology community.

Reportedly, in the preliminary data conducted on 15 patients who had finished a minimum of 12 weeks of therapy, greater response rate of more than 50% was witnessed in both the endpoints. Additionally, PRN1008 is claimed to be well-tolerated in all studies, which showed no episodes of thrombotic or bleeding events.

However, these earlier findings might change as more new patients will be progressed and enrolled in the study. Principia Biopharma is also likely to demonstrate an updated data at the forthcoming ASH (American Society of Hematology) Annual Meeting which will be conducted in December.

Incidentally, Principia Biopharma has also prior made headlines when it announced that it would be appointing former Chief Commercial Officer of Kite Pharma, Shawn Tomasello in its Board of Directors

As per Martin Babler, President and Chief Executive Officer, Principia Biopharma, the company is delighted to welcome Shawn in its Board as she brings in a good track record in commercializing and development of pharmaceutical products.

Source Credit: https://ir.principiabio.com/news-releases/news-release-details/principia-announces-positive-preliminary-data-prn1008-immune



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
By Paroma Bhattacharya

Mirati Therapeutics, an oncology company that engages in the development of targeted therapies, recently released its clinical trial results for MRTX849. Reportedly, MRTX849 is a KRAS G12C inhibitor and the data from P...

Best Buy to offer free next-day delivery feature on various products
Best Buy to offer free next-day delivery feature on various products
By Paroma Bhattacharya

Online retailers are always launching new and attractive deals during the holiday season, as it grosses the highest sale time for the year. Several retailer rollout out attractive offers, such as discounts or complimen...

Nature Tech Corp partners with Aldevron for gene therapy manufacturing
Nature Tech Corp partners with Aldevron for gene therapy manufacturing
By Paroma Bhattacharya

The global cell and gene therapy sector is expected to witness a thriving period of growth over the forthcoming years. In fact, owing to the favorable growth conditions across the industry, numerous biotechnology and p...